(Hypertension. 1999;33:1025-1030.)
© 1999 American Heart Association, Inc.
Scientific Contributions |
Local Renin-Angiotensin System Is Involved in K+-Induced Aldosterone Secretion from Human Adrenocortical NCI-H295 Cells
From the Department of Internal Medicine III, University of Leipzig Germany (U.H.); the Department of Pharmacology, University of Heidelberg Germany (J.P.); the Section on Pharmacology, National Institute of Mental Health, Bethesda, Md (F.M.A.C., O.J., J.M.S.); and the National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Md (S.R.B., M.E.-B.). Present address of F.M.A. Correa: Department of Pharmacology, School of Medicine of Ribeirao Preto, University of Sao Paolo, Brazil.
Correspondence to Monika Ehrhart-Bornstein, PhD, NICHD, NIH, Bldg 10, Room 10N262, 10 Center Dr, MSC 1862, Bethesda, MD 20892-1862. E-mail monika.eb{at}worldnet.att.com
 |
Abstract |
|---|
 Top Abstract IntroductionMethodsResultsDiscussionReferences |
|---|
Abstract—NCI-H295, a human adrenocarcinoma cell line, has been proposed as a model system to define the role of the renin-angiotensin system in the regulation of aldosterone production in humans. Because the precise cellular localization of the components of the renin-angiotensin system in human adrenal cortical cells remains unclear, we investigated their localization in this defined cell system. NCI-H295 cells expressed both angiotensinogen and renin as shown by reverse transcriptase polymerase chain reaction and immunohistochemistry. Human angiotensin-converting enzyme (ACE) was not detectable by immunocytochemistry, ACE binding, or reverse transcriptase polymerase chain reaction. However, 3.5 mmol/L K+ stimulated the formation of both angiotensin I and angiotensin II 1.9- and 2.5-fold, respectively, and increased aldosterone release 3.0-fold. The K+-induced stimulation of aldosterone release was decreased by captopril and enalaprilat (24% and 26%, respectively) and by the angiotensin type 1 (AT1)-receptor antagonist losartan (28%). Angiotensin II–induced stimulation of aldosterone release was abolished by losartan treatment. Specific [125I]Sar1-angiotensin II binding was detected by receptor autoradiography. The binding of [125I]Sar1-angiotensin II was completely displaced by the AT1 antagonist losartan but not by the AT2 receptor ligand PD 123319, confirming the expression of angiotensin II AT1 receptors in NCI-H295 cells. Our results demonstrate that NCI-H295 cells express most of the components of the renin-angiotensin system. Our failure to detect ACE, however, suggests that the production of angiotensin II in NCI-H295 cells may be ACE independent. NCI-H295 cells are able to produce angiotensin II, and K+ increases aldosterone secretion in part through an angiotensin-mediated pathway. The production of angiotensin II in NCI-H295 cells demonstrates that this human cell line can be useful to characterize the role of locally produced angiotensin II in the regulation of aldosterone release.
Key Words: NCI-H295 cell line • renin-angiotensin system • angiotensin II • aldosterone • potassium
|
Introduction |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
The renin-angiotensin-system (RAS) plays an important role in the regulation of blood pressure as well as sodium and volume homeostasis.1 In addition to the circulating RAS, local RAS have been documented in a number of animal and human tissues including the adrenal gland (for review, see Reference 2 ). In the adrenal cortex, the role of the local RAS has not been fully characterized.3 4 5 The human adrenal zona glomerulosa expresses all the components of the RAS, including angiotensinogen (AOG), renin, and angiotensin-converting enzyme (ACE)2 5 as well as the prohormone convertase PC5 mRNA.6 Locally produced angiotensin II (Ang II) has been proposed to exercise an autocrine/paracrine control of aldosterone secretion.2 In many tissues, the various components of the RAS are found in different cells,7 and it is not clear whether the components of the adrenocortical RAS are produced by different cells or if one cell contains all components. Precise data on the localization and regulation of the RAS components are a requirement for the investigation and interpretation of this system. The examination of an isolated adrenal RAS is especially important to differentiate between the effects caused by circulating and local adrenal systems.
The human adrenocortical carcinoma cell line NCI-H295 is a widely accepted model for human adrenocortical studies. This cell line, originally cultured from a human adrenocortical tumor in 1980, represents the first cell line to maintain the ability to produce all adrenocortical steroids, expressing the 3 major pathways of adrenal steroidogenesis including the main steroidogenic enzymes.8 As in normal human adrenocortical cells, synthesis of aldosterone is regulated by Ang II through AT1 receptors9 10 and potassium.11 These cells therefore may be a suitable system for the characterization of a local RAS. We asked the questions whether the complete RAS system was coexpressed in NCI-H295 cells, whether these cells could produce Ang II after stimulation, whether the increase in aldosterone release after Ang II could be modified by inhibition of Ang II synthesis or blockade of AT1 receptors, and whether K+-stimulated aldosterone release was dependent on Ang II.
|
Methods |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Cell Culture
NCI-H295 cells were grown at 37°C in a 5% CO2 humidified atmosphere in RPMI 1640 (Gibco BRL) containing hydrocortisone (3.625 µg/L), insulin (5 µg/mL), transferrin (100 mg/L), estradiol (2.724 µg/L), selenite (5 µg/L), 2% fetal calf serum, and antibiotics. For immunohistochemistry, adherent cells were selected and grown on culture slides for 48 hours in the above medium and for 24 hours in serum-free medium containing ascorbic acid (10-7 mol/L), transferrin (100 mg/L), BSA (0.01% wt/vol), and bacitracin (0.01% wt/vol). Viability of cells was
90% by trypan blue exclusion test. Culturing of human
adrenal cells has been described in detail.12
RNA Extraction and Reverse Transcriptase Polymerase Chain
Reaction
Total RNA was isolated from 5x106
NCI-H295 cells (RNAeasy Kit), treated with DNAse I (Boehringer
Mannheim GmbH) and screened for contamination with genomic DNA in a
control polymerase chain reaction (PCR) for GAPDH. cDNA was synthesized
(First Strand cDNA synthesis kit, Boehringer Mannheim) and
amplified with the use of specific primers for GAPDH (as a control for
reverse transcriptase [RT]), AOG, and renin
(Table). No genomic DNA was
amplified when using nontranscribed mRNA. In all amplifications,
negative controls without cDNA were included. cDNA from human adrenal,
cultured human adrenal cells, and lung were applied as internal
controls (normal human lung was kindly provided by G. Hoheisel,
Leipzig, Germany).
|
The PCR products for AOG and renin were verified by digestion with HaeIII/TaiI (AOG) and GsuI (renin) and by dideoxy sequencing with thermosequenase and dye-labeled terminator chemistry (Amersham). RT-PCR was repeated with different RNA isolations from different passages of NCI-H295 cells.
Immunohistochemistry
Cells were fixed in 70% ethanol for 15 minutes and
immunostained for AOG (rabbit anti-AOG, 1:200;
Diagnostic International), renin (rabbit antirenin, 1:100;
Diagnostic International), and ACE (monoclonal antibody MAB
4057, 1:50 to 1:500; Biozol). As controls, antigen-preincubated
antibodies (10-fold excess) were applied. Bound antibodies were
detected by the streptavidin-biotin-peroxidase method (Dianova) with
AEC (3-amino-9-ethylcarbazole) as described previously.12
No staining was observed in control sections in which the antibodies
were replaced by rabbit IgG or mouse IgG, respectively.
Incubation Procedure and Hormone Measurements
NCI-H295 suspension cells were incubated with secretagogues
and/or inhibitors after 24 hours of preincubation in
serum-free medium. In a typical set of experiments,
2.5x105 cells/750 µL were incubated with
3.5 mmol/L or 9 mmol/L K+ with or
without the simultaneous incubation with the ACE
inhibitors (ACEIs) captopril or enalaprilat (Merck Sharp &
Dohme) or the Ang II type 1 (AT1) receptor
antagonist losartan (Merck Sharp & Dohme). In
another set, cells were incubated with Ang II
(10-6 to 10-9 mol/L) and
losartan (10 µmol/L).
Aldosterone concentrations in the medium were measured by radioimmunoassay (Immunotech). For determination of Ang I and Ang II, see Reference 13 . Addition of 3.5 mmol/L or 9 mmol/L K+ to the medium did not influence either assay.
ACE Activity
ACE activity was determined in 106
cells/assay from different cultivation days. Cells were washed twice
with PBS, centrifuged, and the pellet resuspended in 0.1 mol/L
TES, pH 7.2, containing 0.3% Triton X100. Fifty microliters of the
sample (or buffer as reference) was incubated at 37°C for 1 hour with
400 µL phosphate buffer, pH 8.0, and 50 µL substrate (10
mmol/L Z-Phe-His-Leu; Bachem) with or without 10 µmol/L
captopril or 10 µmol/L enalaprilat. The reaction was terminated
by removing 100 µL and addition to 1 mL 0.1N NaOH at ambient
temperature. Subsequently, complex formation between L-His-L-Leu and
the reagent was measured, using 100 µL (180 µmol/L)
L-His-L-Leu (Bachem) as standard. Twenty-five microliters of
orthophtaldialdehyde was added, and the mixture was incubated for 30
minutes in the dark. Reaction was terminated by addition of 0.8N HCL (1
mL), and after centrifugation (3000 rpm, 5 minutes),
fluorescence was monitored for 1 hour (fluorescence
spectrometer RF-1502, Shimadzu).
ACE Binding
NCI-H295 cells were washed twice with PBS and
106 cells were pelleted by
centrifugation (573g, 4°C for 10 minutes).
Cryostat sections (16 µm) of these pellets and human adrenals
were cut at –20°C. Binding of [125I] 351A to
ACE was performed as described earlier.14 Compound
351A is the p-hydroxybenzamidine derivative of MK 521
(lisinopril), which in turn is the Lys-Pro analogue of MK
422, the active diacid from of the specific inhibitor
enalapril (MK421). It was iodinated by DuPont New England
Nuclear to a specific activity of 2000 Ci/mmol.
Optical densities in the autoradiograms were measured by computerized microdensitometry with the use of the NIH Image 1.61 analysis system. [125I] 351A concentrations were quantified by comparison with [125I]-labeled microscales and transformed to corresponding values of femtomoles per milligram of protein.15 Data were analyzed with the use of GraphPAd Prism Software.
Ang II Receptor Binding
Sar1-Ang II was iodinated by
New England Nuclear to a specific activity of 2200 Ci/mmol. Competition
studies were conducted by incubating consecutive sections of NCI-H295
cell pellets with
[125]Sar1-Ang II and
increasing concentrations of Ang II (10-11 to
10-5 mol/L; Peninsula) or selective ligands for
AT1 (losartan,
10-11 to 10-5 mol/L;
DuPont) or AT2 (PD 123319,
10-11 to 10-5 mol/L;
Parke-Davis) as described earlier.14 Quantitative
autoradiography was performed as described for ACE
binding.
3H-Thymidine Incorporation Assay
Cells were plated on 96-well dishes (105
cells/well) and incubated in serum-free medium for 24 hours in the
presence of either 3.5 mmol/L or 9 mmol/L
K+ with or without the addition of captopril or
enalaprilat, the AT1 receptor
antagonist losartan, or with the
inhibitors alone. To assess proliferation, cells were
incubated with 2.5 mCi/mL 3H-thymidine
(Peninsula) for 24 hours, removed from the culture plate by repeated
pipetting, and 3H-thymidine incorporation was
assayed.16
Statistical Analysis
Results are expressed as mean±SEM, and statistical significance
was determined by ANOVA with the software package SPSS for Windows,
version 6. Differences were considered significant at
P<0.05. All experiments were repeated for a minimum of 3
different cell passages with 4 wells per experiment.
|
Results |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
The present study provides proof for a complete functional RAS in the human adrenocortical cell line NCI-H295. RT-PCR for AOG mRNA and renin mRNA yielded the expected cDNA fragments of 320 bp for AOG (Figure 1A) and 306 bp for renin (Figure 1B). Enzymatic digestion of the PCR product for AOG with HaeIII/TaiI led to 2 fragments with the correct sizes of 230 bp/90 bp (HaeIII) and 190/130 bp (TaiI), and digestion of the PCR product for renin with the use of GsuI resulted in the expected pattern of 262 bp/44 bp. Identity of PCR products was also confirmed by subsequent sequencing (data not shown). No expression of ACE mRNA was observed in NCI-H295 cells (Figure 1C).
|
Immunohistochemical staining for AOG (Figure 2A) and renin (Figure 2C) revealed
98% positive NCI-H295 cells. Preincubation of the antibodies with
their respective antigen completely suppressed
immunostaining, confirming the specificity of the
staining (Figure 2, B and D). The staining intensity varied
interindividually in the 4 different passages, but the number of
stained cells was unchanged. No staining for ACE was observed in these
cells, whereas controls (lung, normal adrenal) showed the expected
positive reaction (data not shown).
|
In response to 12 hours of incubation with 3.5 mmol/L and 9 mmol/L K+, the aldosterone secretion in NCI-H295 cells increased 3-fold (P<0.001) and 4.4-fold (P<0.001), respectively (Figure 3). This K+-induced stimulation was reduced by addition of both ACE inhibitors. Enalaprilat (10 µmol/L) reduced aldosterone secretion after 3.5 mmol/L K+ by 25.5% (P<0.001) and after 9 mmol/L K+ by 12.8% (P<0.05). Captopril (10 µmol/L) reduced the effects of K+ (3.5 mmol/L and 9 mmol/L) by 23.5% (P<0.05) and by 12.1% (P<0.05), respectively (Figure 3).
|
The AT1 receptor antagonist losartan (10 µmol/L) significantly inhibited K+-stimulated aldosterone secretion. Coincubation with 3.5 mmol/L K+ reduced aldosterone secretion by 27.6% (P<0.001) and aldosterone secretion induced by 9 mmol/L K+ by 24.8% (P<0.001) (Figure 3).
Incubation with 3.5 mmol/L K+ and 9 mmol/L K+ stimulated the formation of Ang I and Ang II by NCI H295 cells. Addition of 3.5 mmol/L K+ for 12 hours resulted in a 2.0-fold increase in Ang I (P<0.05) and a 4.9-fold increase in Ang II (P<0.001) concentrations in the medium (Figure 4). Ang II at concentrations of 1 to 1000 nmol/L dose-dependently stimulated aldosterone release. Losartan at 10 µmol/L totally inhibited aldosterone secretion induced by Ang II at concentrations of 1 to 100 nmol/L (Figure 5).
|
|
3H-thymidine incorporation was not influenced by the addition by K+ (3.5 mmol/L or 9 mmol/L), captopril (10 µmol/L), enalaprilat (10 µmol/L), or losartan (10 µmol/L) or by coincubation of potassium with the ACEIs or the AT1 receptor antagonist losartan. There were no significant changes in 3H-thymidine incorporation during 24 hours.
ACE-like activity was measured in membrane preparations of NCI-H295 cells (14.40±2.51 ng L-His-L-Leu/min per milligram of membranes). This activity could be suppressed completely by addition of 10 µmol/L captopril and reduced by 60% (P<0.01) by addition of 10 µmol/L enalaprilat to the incubation mixture (Figure 6). Binding of [125I] 351A to ACE was not found in the NCI-H295 cells, whereas human adrenal glands were found to bind specifically [125I] 351A.
|
Specific [125I]Sar1-Ang II binding was detected by receptor autoradiography in pellet sections of NCI-H295 cells. The binding of [125I]Sar1-Ang II was completely displaced by the AT1 antagonist losartan (Figure 7A) but not by the AT2 receptor ligand PD 123319 (Figure 7A), confirming the expression of Ang II AT1 receptors in NCI-H295 cells. Competition experiments revealed that [125I]Sar1-Ang II binding was displaced by Ang II and losartan with an IC50 of 7.2x10-9 mol/L and 4.9x10-8 mol/L, respectively (Figure 7B).
|
|
Discussion |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
The present study demonstrates that renin and AOG coexist in the human adrenocortical carcinoma cell line NCI-H295 and that these cells, on K+ stimulation, produce physiologically active Ang II, resulting in a modulation of aldosterone secretion. The presence of AOG and renin mRNA in both normal and pathological human adrenal tissue has been demonstrated in normal and abnormal human glomerulosa, fasciculata, and medullary cells.17 We have demonstrated that both AOG and renin mRNA are expressed in NCI-H295 cells. Both AOG and renin were produced by the cells themselves rather than taken up from the medium, since cultivation in serum-free medium did not decrease immunostaining.
The last step in Ang II formation is the conversion of Ang I to Ang II, which, in the classic RAS, requires ACE. Indeed, NCI-H295 cells were able to increase the formation of Ang I and Ang II on K+ stimulation (see below) and expressed ACE activity that could be inhibited by the ACEIs captopril and enalaprilat. However, neither ACE mRNA, immunoreactive ACE, or [125I]351A binding to ACE could be detected in NCI-H295 cells. ACE binding has been previously demonstrated in human zona glomerulosa cells,18 and we detected [125I]351A binding to sections from human adrenals in our experiments. We therefore can postulate that in NCI-H295, a peptidase other than ACE is active in the conversion of Ang I to Ang II. Such peptidase is recognized by captopril and enalaprilat but not by the anti-ACE antibody or the [125I]351A ligand and has a nucleotide sequence with a low homology to that of ACE. The existence of non-ACE pathways catalyzing Ang I to Ang II has been reported in different tissues.19 20 21 22 Non-ACE kinases that could be inhibited by ACE inhibitors include enzymes that are related to, or isomers of, ACE23 24 or aminopeptidase P,25 or those that are related to endopeptidase 24.15.24 Therefore, the absence of ACE binding in the NCI-H295 cells with a concurrent decrease of aldosterone release by ACEIs suggests a non-ACE activity. The inhibition of ACE activity by enalaprilat or captopril despite absence of [125I]351A binding to the cells probably is due to higher selectivity of lisinopril to ACE.25 It remains to be elucidated if this ACE-like activity is expressed by normal human adrenocortical cells.
Our results indicate that the NCI-H295 RAS could be activated by K+, resulting in increased formation of Ang II and its precursor Ang I, an effect that was maximum at 3.5 mmol/L K+, in accordance with data from rat adrenal.26 At this concentration, Ang II concentrations were enhanced 5 times over basal levels. We also show that Ang II–induced aldosterone release could be totally blocked by losartan, indicating that Ang II is physiologically active in NCI-H295 cells by stimulation of an AT1 receptor, as it has been previously demonstrated in this cell line and in human and rat adrenocortical cells.9 26 27 The expression of AT1 receptors and not AT2 receptors could be confirmed by binding studies.
Potassium stimulated the secretion of aldosterone in NCI-H295 cells, an effect partially inhibited (by 20% to 28%) by captopril, enalaprilat, and losartan. This indicated an involvement of the local RAS, and of locally formed Ang II, as one of the mechanisms activated by K+ in the modulation of aldosterone release. It is well known that potassium is a potent regulator of aldosterone secretion by opening plasma membrane Ca2+ channels in adrenal zona glomerulosa cells and thus increasing intracellular Ca2.28 This Ca2+ signaling pathway also is involved in K+-induced stimulation of steroidogenesis in NCI-H295 cells.11 Therefore, K+ stimulates aldosterone directly by an increase in intracellular Ca2+ and, to a lesser extent, indirectly by the formation of Ang II. A contribution of the adrenal RAS in K+-induced aldosterone release has been suggested from animal models such as rat adrenocortical preparations26 29 30 and bovine adrenocortical cells in primary culture.31
Our observation that Ang II is produced by the steroid-producing cells themselves supports the hypothesis that Ang II regulates the secretion of aldosterone in an autocrine/paracrine manner. This is in agreement with data from other experimental systems, for example, superfused rat glomerulosa tissue and dispersed cells, in which the secretion of aldosterone and Ang II were highly significantly correlated.32 In addition to these acute effects, the local RAS may be required to maintain adrenocortical cells in an appropriate functional state. In the hypertensive transgenic (TGR mRen-2)27 rats that are transfected with the Ren-2 mouse renin gene,33 high concentrations of adrenal renin exist, not only in the glomerulosa but also in inner adrenocortical zones. In these animals, aldosterone production was also found in the inner adrenocortical zones, indicating that one role of the adrenal RAS may be to support aldosterone synthase expression.34 35
In conclusion, our experiments provide evidence that a local RAS exists in the human adrenocortical NCI-H295 cell line. These cells express AOG, renin, Ang I and II, and AT1 receptors. The conversion of Ang I to Ang II in NCI-H295 cells is catalyzed by a peptidase different from human ACE. The identity of this enzyme remains to be elucidated. Both Ang II and aldosterone production can be triggered by a potassium challenge, and blockade of Ang II formation or Ang II AT1 receptors significantly decreases potassium-stimulated aldosterone release. Therefore this RAS fulfills all criteria of a functional autocrine system under the control of physiological stimuli. These cells are the first human model used to study the function of adrenal RAS and its involvement in the regulation of adrenocortical steroidogenesis. Although these cells are tumor cells that might differ from normal adrenal cells in some respects, the NCI-H295 cell line appears to be a highly suitable and attractive model system toward a better understanding of the regulation of local RAS in human cells and ultimately its implication on hypertension.
|
Acknowledgments |
|---|
This study was supported by the Deutsche Forschungsgemeinschaft (grants Bo1141/2-3 to S.R.B and PE 366/3-2 to J.P.) and the Willhelm Sander Stiftung (grant 95.033.1 to M.E.B.). We thank Merck Sharp & Dohme for providing losartan. In addition, we thank Silke Brauer, Sandy Laue, and Jutta Zimmer for their excellent technical assistance and the National Institutes of Health Scientific Computer Resource Center for image processing.
Received October 1, 1998; first decision October 27, 1998; accepted December 14, 1998.
|
References |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
1. Peach MJ. Renin-angiotensin system: biochemistry and mechanisms of action. Physiol Rev. 1977;57:313–370.
2.
Ehrhart-Bornstein M, Hinson JP, Bornstein SR,
Scherbaum WA, Vinson GP. Intraadrenal interactions in the regulation of
adrenocortical steroidogenesis. Endocr Rev. 1998;19:101–143.
3. Peters J, Ganten D. Adrenal renin expression and its role in ren-2 transgenic rats TGR(mREN2)27. Horm Metab Res. 1998;30:350–354.[Medline] [Order article via Infotrieve]
4. Vinson GP, Ho MM. The adrenal renin/angiotensin system in the rat. Horm Metab Res. 1998;30:355–359.[Medline] [Order article via Infotrieve]
5. Mulrow PJ. Renin-angiotensin system in the adrenal. Horm Metab Res. 1998;30:346–349.[Medline] [Order article via Infotrieve]
6.
Mercure C, Jutras I, Day R, Seidah NG, Reudelhuber TL.
Prohormone convertase PC5 is a candidate processing enzyme for prorenin
in the human adrenal cortex. Hypertension. 1996;28:840–846.
7. Ganong WF. Origin of the angiotensin II secreted by cells. Proc Soc Exp Biol Med. 1994;205:213–219.[Medline] [Order article via Infotrieve]
8.
Gazdar AF, Oie HK, Shackleton CH, Chen TR, Triche TJ,
Myers CE. Establishment and characterization of a human adrenocortical
carcinoma cell line that expresses multiple pathways of steroid
biosynthesis. Cancer Res. 1990;50:5488–5496.
9. Bird IM, Mason JI, Rainey WE. Hormonal regulation of angiotensin II type 1 receptor expression and AT1-R mRNA levels in human adrenocortical cells. Endocr Res. 1995;21:169–182.[Medline] [Order article via Infotrieve]
10.
Bird IM, Hanley NA, Word RA, Mathis JM, McCarthy JL,
Mason JI. Human NCI-H295 adrenocortical carcinoma cells: a model for
angiotensin-II-responsive aldosterone
secretion. Endocrinology. 1993;133:1555–1561.
11. Bird IM, Mathis JM, Mason JI, Rainey WE. Ca2+-regulated expression of steroid hydroxylases in H295R human adrenocortical cells. Endocrinology. 1995;136:5677–5684.[Abstract]
12.
Glasow A, Breidert M, Haidan A, Anderegg U, Kelly PA,
Bornstein SR. Functional aspects of the effect of prolactin (PRL) on
adrenal steroidogenesis and distribution of the PRL receptor in the
human adrenal gland. J Clin Endocrinol Metab. 1996;81:3103–3111.
13. Peters J, Hilgers KF, Masergluth C, Kreutz R. Role of the circulating renin-angiotensin system in the pathogenesis of hypertension in transgenic rats, TGR (mREN2) 27. Clin Exp Hypertens. 1996;18:933–948.
14. Jöhren O, Imboden H, Hauser W, Maye I, Sanvitto GL, Saavedra JM. Localization of angiotensin-converting enzyme, angiotensin II, angiotensin II receptor subtypes, and vasopressin in the mouse hypothalamus. Brain Res. 1997;757:218–227.[Medline] [Order article via Infotrieve]
15. Nazarali AJ, Gutkind JS, Saavedra JM. Calibration of 125I-polymer standards with 125I-brain paste standards for use in quantitative receptor autoradiography. J Neurosci Methods. 1989;30:247–253.[Medline] [Order article via Infotrieve]
16.
Haidan A, Bornstein SR, Glasow A, Uhlmann K,
Lübke C, Ehrhart-Bornstein M. Basal steroidogenic activity of
adrenocortical cells is increased 10-fold by coculture with chromaffin
cells. Endocrinology. 1998;139:772–780.
17. Racz K, Pinet F, Gasc JM, Guyene TT, Corvol P. Coexpression of renin, angiotensinogen, and their messenger ribonucleic acids in adrenal tissues. J Clin Endocrinol Metab. 1992;75:730–737.[Abstract]
18. Gonzalez-Garcia C, Keiser HR. Angiotensin II and angiotensin converting enzyme binding in human adrenal gland and pheochromocytomas. J Hypertens. 1990;8:433–441.[Medline] [Order article via Infotrieve]
19. Dzau VJ, Sasamura H, Hein L. Heterogeneity of angiotensin synthetic pathways and receptor subtypes: physiological and pharmacological implications. J Hypertens Suppl. 1993;11:S13–S18.
20.
Saye JA, Ragsdale NV, Carey RM, Peach MJ. Localization
of angiotensin peptide-forming enzymes of 3T3–F442A
adipocytes. Am J Physiol. 1993;264:C1570–C1576.
21. Urata H, Nishimura H, Ganten D. Mechanisms of angiotensin II formation in humans. Eur Heart J. 1995;16(suppl N):79–85.
22. Urata H, Nishimura H, Ganten D, Arakawa K. Angiotensin-converting enzyme-independent pathways of angiotensin II formation in human tissues and cardiovascular diseases. Blood Press Suppl. 1996;2:22–28.[Medline] [Order article via Infotrieve]
23.
Strittmatter SM, Thiele EA, Kapiloff MS, Snyder SH. A
rat brain isozyme of angiotensin-converting enzyme: unique
specificity for amidated peptide substrates. J Biol
Chem. 1985;260:9825–9832.
24.
Genden EM, Molineaux CJ. Inhibition of
endopeptidase-24.15 decreases blood pressure in
normotensive rats. Hypertension. 1991;18:360–365.
25.
Hooper NM, Hryszko J, Oppong SY, Turner AJ.
Inhibition by converting enzyme inhibitors of pig kidney
aminopeptidase P. Hypertension. 1992;19:281–285.
26.
Chiou CY, Kifor I, Moore TJ, Williams GH. The effect of
losartan on potassium-stimulated aldosterone
secretion in vitro. Endocrinology. 1994;134:2371–2375.
27. Naville D, Lebrethon MC, Kermabon AY, Rouer E, Benarous R, Saez JM. Characterization and regulation of the angiotensin II type-1 receptor (binding and mRNA) in human adrenal fasciculata-reticularis cells. FEBS Lett. 1993;321:184–188.[Medline] [Order article via Infotrieve]
28. Quinn SJ, Williams CH. Regulation of aldosterone secretion. In: James VHT, ed. The Adrenal Gland. New York, NY: Raven Press; 1992:159–189.
29.
Shier DN, Kusano E, Stoner GD, Franco-Saenz R, Mulrow
PJ. Production of renin, angiotensin II, and
aldosterone by adrenal explant cultures: response to
potassium and converting enzyme inhibition. Endocrinology. 1989;125:486–491.
30.
Yamaguchi T, Naito Z, Stoner GD, Franco-Saenz R, Mulrow
PJ. Role of the adrenal renin-angiotensin system on
adrenocorticotropic hormone- and potassium-stimulated
aldosterone production by rat adrenal glomerulosa
cells in monolayer culture. Hypertension. 1990;16:635–641.
31.
Gupta P, Franco-Saenz R, Mulrow PJ. Locally generated
angiotensin-II in the adrenal-gland regulates basal,
corticotropin-stimulated, and potassium-stimulated
aldosterone secretion. Hypertension. 1995;25:443–448.
32.
Kifor I, Moore TJ, Fallo F, Sperling E, Chiou CY,
Menachery A. Potassium-stimulated angiotensin release from
superfused adrenal capsules and enzymatically dispersed cells of the
zona glomerulosa. Endocrinology. 1991;129:823–831.
33. Mullins JJ, Peters J, Ganten D. Fulminant hypertension in transgenic rats harbouring the mouse Ren-2 gene. Nature. 1990;344:541–544.[Medline] [Order article via Infotrieve]
34.
Sander M, Ganten D, Mellon SH. Role of adrenal renin in
the regulation of adrenal steroidogenesis by corticotropin. Proc
Natl Acad Sci U S A. 1994;91:148–152.
35.
Yamaguchi T, Tokita Y, Franco-Saenz R, Mulrow PJ,
Peters J, Ganten D. Zonal distribution and regulation of adrenal renin
in a transgenic model of hypertension in the rat.
Endocrinology. 1992;131:1955–1962.
This article has been cited by other articles:
 |
|
 |
|
  E. Samandari, P. Kempna, J.-M. Nuoffer, G. Hofer, P. E Mullis, and C. E Fluck Human adrenal corticocarcinoma NCI-H295R cells produce more androgens than NCI-H295A cells and differ in 3{beta}-hydroxysteroid dehydrogenase type 2 and 17,20 lyase activities J. Endocrinol., December 1, 2007; 195(3): 459 - 472. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. G Romero, M. Y. Zhou, L. L Yanes, M. W Plonczynski, T. R Washington, C. E Gomez-Sanchez, and E. P Gomez-Sanchez Regulators of G-protein signaling 4 in adrenal gland: localization, regulation, and role in aldosterone secretion J. Endocrinol., August 1, 2007; 194(2): 429 - 440. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Peters, P. Teubner, S. Clausmeyer, T. Puschner, C. Maser-Gluth, H.-J. Wrede, B. Kranzlin, and J. Peters StAR expression and the long-term aldosterone response to high-potassium diet in Wistar-Kyoto and spontaneously hypertensive rats Am J Physiol Endocrinol Metab, January 1, 2007; 292(1): E16 - E23. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. G. Romero, B. L. Welsh, E. P. Gomez-Sanchez, L. L. Yanes, S. Rilli, and C. E. Gomez-Sanchez Angiotensin II-Mediated Protein Kinase D Activation Stimulates Aldosterone and Cortisol Secretion in H295R Human Adrenocortical Cells Endocrinology, December 1, 2006; 147(12): 6046 - 6055. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. G. Romero, M. W. Plonczynski, E. P. Gomez-Sanchez, L. L. Yanes, and C. E. Gomez-Sanchez RGS2 Is Regulated by Angiotensin II and Functions as a Negative Feedback of Aldosterone Production in H295R Human Adrenocortical Cells Endocrinology, August 1, 2006; 147(8): 3889 - 3897. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Ehrhart-Bornstein, V. Lamounier-Zepter, A. Schraven, J. Langenbach, H. S. Willenberg, A. Barthel, H. Hauner, S. M. McCann, W. A. Scherbaum, and S. R. Bornstein Human adipocytes secrete mineralocorticoid-releasing factors PNAS, November 25, 2003; 100(24): 14211 - 14216. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Brede, K. Hadamek, L. Meinel, F. Wiesmann, J. Peters, S. Engelhardt, A. Simm, A. Haase, M. J. Lohse, and L. Hein Vascular Hypertrophy and Increased P70S6 Kinase in Mice Lacking the Angiotensin II AT2 Receptor Circulation, November 20, 2001; 104(21): 2602 - 2607. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Dechow, C. Morath, J. Peters, I. Lehrke, R. Waldherr, V. Haxsen, E. Ritz, and J. Wagner Effects of all-trans retinoic acid on renin-angiotensin system in rats with experimental nephritis Am J Physiol Renal Physiol, November 1, 2001; 281(5): F909 - F919. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Mazzocchi, L. K. Malendowicz, A. Markowska, G. Albertin, and G. G. Nussdorfer Role of adrenal renin-angiotensin system in the control of aldosterone secretion in sodium-restricted rats Am J Physiol Endocrinol Metab, June 1, 2000; 278(6): E1027 - E1030. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Kantachuvesiri, S. Fleming, J. Peters, B. Peters, G. Brooker, A. G. Lammie, I. McGrath, Y. Kotelevtsev, and J. J. Mullins Controlled Hypertension, a Transgenic Toggle Switch Reveals Differential Mechanisms Underlying Vascular Disease J. Biol. Chem., September 21, 2001; 276(39): 36727 - 36733. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||